396-01-0 Usage
Uses
Used in Pharmaceutical Industry:
2,4,7-Triamino-6-phenylpteridine is used as a diuretic agent for the treatment of edema caused by various reasons such as circulatory insufficiency, cirrhosis of the liver, and nephrotic syndrome. It functions as a potassium-sparing diuretic, inhibiting the urinary excretion of potassium and blocking Na+ reuptake in the kidneys. 2,4,7-Triamino-6-phenylpteridine is also recommended in combination with other diuretics to enhance the treatment of edema.
Used in Analytical Chemistry:
2,4,7-Triamino-6-phenylpteridine is used as an analytical reference standard due to its distinct chemical properties, such as its high melting point and blue fluorescence under acidic conditions. This makes it a valuable tool for researchers and scientists in the field of analytical chemistry for the identification and quantification of similar compounds.
Used in Drug Development:
The unique structure and properties of 2,4,7-Triamino-6-phenylpteridine make it a promising candidate for the development of new drugs targeting various medical conditions. Its potential applications in the pharmaceutical industry can be further explored through research and development efforts, focusing on its interaction with biological systems and its ability to modulate specific signaling pathways.
Originator
Jatropur,Rohm,W. Germany,1962
Manufacturing Process
To a solution of 9 grams of 5-nitroso-2,4,6-triaminopyrimidine in 500 mi of
refluxing dimethylformamide is added 9 grams of phenylacetonitrile and the
refluxing is stopped. The 3 grams of anhydrous sodium methoxide is added
and the mixture is refluxed for 15 minutes. The mixture is chilled and the
solid is filtered and washed several times with warm water until the washings
are neutral. Drying gives yellow crystals which are recrystallized with a Darco
treatment from formamide-water heating the solution no hotter than 125°C.
This product is then suspended in filtered deionized water and warmed for 15
minutes. This yields the 2,4,7-triamino-6-phenylpteridine as yellow crystals
with a MP of 314° to 317°C.
Therapeutic Function
Diuretic
Biological Functions
Triamterene (Dyrenium)
results in changes in urinary electrolyte
patterns that are qualitatively similar to those produced
by spironolactone. The mechanism by which this
agents bring about the alterations in electrolyte loss,
however, is quite different. Triamterene
produces this effects whether or not aldosterone or any
other mineralocorticoid is present. The action of this
drug is clearly unrelated to endogenous mineralocorticoid
activity, and this drug is effective in adrenalectomized
patients.
Air & Water Reactions
Sensitive to light; slowly oxidized upon exposure to air. Insoluble in water.
Reactivity Profile
2,4,7-Triamino-6-phenylpteridine neutralizes acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen may be generated in combination with strong reducing agents, such as hydrides.
Fire Hazard
Flash point data for 2,4,7-Triamino-6-phenylpteridine are not available; however, 2,4,7-Triamino-6-phenylpteridine is probably combustible.
Mechanism of action
Triamterene is a pyrazine derivative that inhibits reabsorption of sodium ions without
increasing excretion of potassium ions. It exhibits the same approximate effect as spironolactone;
however, it does not competitively bind with aldosterone receptors. Its action does
not have an effect on secretion of aldosterone or its antagonists, which are a result of direct
action on renal tubules.
This potassium sparing diuretic causes a moderate increase in excretion of sodium and
bicarbonate ions in urine, and it raises excretion of potassium and ammonia ions. It has little
effect on urine volume.
Clinical Use
Triamterene can be used in the treatment of congestive
heart failure, cirrhosis, and the edema caused by
secondary hyperaldosteronism. It is frequently used in
combination with other diuretics except spironolactone.
Amiloride, but not triamterene, possesses antihypertensive
effects that can add to those of the thiazides.
These K+-sparing diuretics have low efficacy when
used alone, since only a small amount of total Na reabsorption
occurs at more distal sites of the nephron.
These compounds are used primarily in combination
with other diuretics, such as the thiazides and loop diuretics,
to prevent or correct hypokalemia. The availability
of fixed-dose mixtures of thiazides with nonsteroidal
K+-sparing compounds has proved a rational
form of drug therapy. Both triamterene and amiloride
are available alone or in combination with hydrochlorothiazide.
Side effects
Because the actions of triamterene and amiloride
are independent of plasma aldosterone levels, their prolonged
administration is likely to result in hyperkalemia.
Both amiloride and triamterene are contraindicated
in patients with hyperkalemia.Triamterene
should not be given to patients with impaired renal
function. Potassium intake must be reduced, especially
in outpatients.A folic acid deficiency has been reported
to occur occasionally following the use of triamterene.
Synthesis
Triamterene, 2,4,7-triamino-6-phenylpteridine (21.5.13), is synthesized in by
the following scheme. Reacting guanidine with malonodinitrile gives 2,4,6-triaminopyrimidine
(21.5.11). This undergoes nitrosation by reacting it with nitric acid, which results in the formation of 5-nitroso-2,4,6-triaminopyrimidine (21.5.12), which upon condensation with
benzyl cyanide in the presence of sodium methoxide cyclizes into triamterene (21.5.13).
Veterinary Drugs and Treatments
Triamterene is a potassium-sparing diuretic that potentially could
be used as an alternative to spironolactone for the adjunctive treatment
of congestive heart failure in dogs, however, there is little experience
associated with its use in dogs or cats.
Drug interactions
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
enhanced hypotensive effect (risk of severe
hyperkalaemia).
Analgesics: increased risk of nephrotoxicity with
NSAIDs; increased risk of hyperkalaemia, especially
with indometacin; antagonism of hypotensive effect.
Antibacterials: avoid concomitant use with
lymecycline.
Antidepressants: enhanced hypotensive effect with
MAOIs; increased risk of postural hypotension with
tricyclics.
Antipsychotics: enhanced hypotensive effect with
phenothiazines.
Antihypertensives: enhanced hypotensive effect;
increased risk of first dose hypotensive effect of postsynaptic alpha-blockers, e.g. prazosin.
Ciclosporin: increased risk of hyperkalaemia.
Cytotoxics: increased risk of nephrotoxicity and
ototoxicity with platinum compounds.
Lithium: reduced excretion of lithium (risk of
lithium toxicity).
Potassium salts: increased risk of hyperkalaemia.
Tacrolimus: increased risk of hyperkalaemia.
Metabolism
Triamterene is extensively metabolised apparently via the
cytochrome P450 isoenzyme CYP1A2.
It is mainly excreted in the urine in the form of
metabolites with some unchanged triamterene; variable
amounts are also excreted in the bile.
Check Digit Verification of cas no
The CAS Registry Mumber 396-01-0 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,9 and 6 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 396-01:
(5*3)+(4*9)+(3*6)+(2*0)+(1*1)=70
70 % 10 = 0
So 396-01-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
396-01-0Relevant articles and documents
Synthetic method of triamterene intermediate
-
Paragraph 0015-0017, (2021/07/28)
The invention improves a synthesis method of triamterene from an intermediate to a triamterene finished product. The method adopts guanidine hydrochloride as a starting material to prepare 5-nitroso-2, 4, 6-triaminopyrimidine, and comprises the following steps: (1) sequentially adding water and malononitrile into a reaction kettle, stirring for 25 minutes for dissolving, starting nitrogen protection, adding a sodium nitrite saturated solution at 20 DEG C, dropwise adding 8% HCl at the same time for adjusting the pH value to 3-4, after the sodium nitrite aqueous solution is dropwise added, keeping the temperature for 2.5 hours at 18 DEG C, wherein the dosage weight ratio of the water to the sodium nitrite to the malononitrile to the 8% hydrochloric acid is as follows: the use mass ratio of the sodium nitrite to the malononitrile to the 8% hydrochloric acid is 2.5:1.15:1:0.35; and (2) adding guanidine hydrochloride solid into the solution obtained in the step (1), and stirring for 30 minutes, and adding NaCO3 solid to adjust the pH value to 9-10, wherein the weight ratio of guanidine hydrochloride to sodium carbonate to malononitrile in (1) is as follows: guanidine hydrochloride to malononitrile to sodium carbonate is 1.60:1:(0.10-0.12). According to the method, the synthesis risk of the triamterene intermediate is reduced, wastewater generated in the refining process is reduced, and safe production, energy conservation and emission reduction are facilitated.
Triamterene compound and preparation method thereof
-
Paragraph 0011; 0013; 0015, (2018/04/02)
The invention relates to a triamterene compound and a preparation method thereof. The triamterene compound is a crystal. The triamterene compound prepared by the method provided by the invention has high purity and good stability, and the preparation method of triamterene has the characteristics of simplicity, stable product quality, and small environmental pollution, and is suitable for further promotion and application.
A preparation method of the pteridine phenalgin (by machine translation)
-
Paragraph 0022-0039, (2017/08/29)
The invention relates to a preparation method of the pteridine phenalgin, comprises the following steps: adding to the condensation reaction kettle 5 - nitroso - 2, 4, 6 - triaminopyrimidine and benzyl cyanide, adding non-proton polar solvent under stirring condition by adding alkaline catalyst, heating to 50 - 120 °C insulation 3 - 10 h after cooling to 0 - 50 °C, filtering to obtain phenalgin pteridine crude product, crude adopts the non-proton polar solvent refining, washing to obtain the final product phenalgin pteridine. The invention using a suitable solvent as reaction and refining solvent, can make the reaction yield 85.7%, effectively reduce the production cost, and reduce the pollutants such as; using a suitable solvent refining, can effectively reduce the refined solvent consumption, improve the purification efficiency, refining solvent can be recycled by distilling and then mechanically, no waste water is produced, environmental pollution is small, the material can be recycled, the purity of the product and the like, suitable for further popularization and application. (by machine translation)
Potassium-neutral salureticum with anti-hypertensive effect
-
, (2008/06/13)
A diuretically active combination comprising furosemide and triamterene in a ratio of 1:1 to 1:2, in which furosemide is in the form of controlled release so as to facilitate solubilization of the furosemide in triamterene micelles to stabilize the combination as mixed micelles of low polydispersity yielding dissolution rates in in vitro tests of furosemide of not more than about 1.5% after about one hour at pH 1.5 to 3.5 and a slow release of not more than about 4.5% at pH 5.5 concurrent with a release of triamterene of about 60-70% and 80%, respectively, and with a release of not more than 85% furosemide after eight hours at pH 7.5 in salt solutions of adjusted pH.
